GlassScriptPhysician profile
Loren Mell
NPI 1316119704
$22,493.75
in general payments reported to CMS, 2019-2025
10 companies · $14K in 2025
The $14K reported for 2025 was more than what 97% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,627 · 2022: $4,725 · 2023: $150 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,960.00 |
| Food and Beverage | $181.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $9,250.00 | 2025 | |
| Pfizer INC. | $4,725.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $4,710.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,836.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,623.74 | 2019 | |
| Merck Sharp & Dohme LLC | $198.73 | 2019-2025 | |
| Genentech, INC. | $150.00 | 2023 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Mell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.